Annual General Meeting of Active Biotech AB


Board members Sven Andréasson, Mats Arnhög, Maria Borelius, Professor Klas Kärre, Peter Sjöstrand and Peter Ström were re-elected by the AGM. The AGM also decided to appoint Mats Arnhög as Chairman of the Board.
The firm of accountants KPMG Bohlins AB with the authorized public accountant Stefan Holmström was elected as Principle Auditors until the AGM 2009.
The AGM decided further that the nomination committee shall have the task to propose a Chairman of the AGM, Chairman of the Board and other members of the Board, Board remunerations and a proposal for the election of Auditors as well as Company Auditors' remunerations. The nomination committee shall be composed of the, on December 31st, three largest owners as well as the Chairman of the Board.
The AGM approved the Board's proposal to authorize the Board to issue, at one or more occasions, with or without preferential right, a total of 6,000,000 new shares.
Sven Andréasson's address to shareholders at the AGM (and the Annual Report) will be available in its entirety at
Lund, April 22, 2005
Active Biotech AB
Sven Andréasson
President & CEO
About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA (TTS), a novel concept for use in cancer immunotherapy.

Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50